Novo Nordisk buyback reaches DKK 9.0 billion of DKK 15 billion program

Novo Nordisk has repurchased just over DKK 9.0 billion of its own B shares, about 60 percent of the DKK 15 billion program it began on February 4, 2026, the Danish drugmaker said in a notice dated September 7, 2026 ^[1][2].

As of September 4, the company had bought 32,034,179 B shares since February 4 at an average price of DKK 281.63 per share, for a total transaction value of DKK 9,021,774,283 ^[1][2]. Novo Nordisk's B shares trade on Nasdaq Copenhagen under the ticker Novo-B, and its American depositary receipts trade on the New York Stock Exchange under the symbol NVO ^[1][2].

A second phase of the buyback began on May 6, 2026, under an authorization to repurchase up to DKK 11,200,000,010.45 in B shares through February 1, 2027 ^[1][2]. That portion had reached 17,275,000 shares for DKK 5,221,774,293 as of September 4 ^[1][2].

Purchases in the most recent stretch ran from DKK 291.92 to DKK 305.35 a share. On August 31 the company bought 210,000 shares at an average of DKK 291.92, for DKK 61,302,771; on September 1, 215,000 shares at DKK 293.94, for DKK 63,196,785; on September 2, 215,000 shares at DKK 297.42, for DKK 63,945,131; on September 3, 215,000 shares at DKK 305.35, for DKK 65,649,697; and on September 4, 200,000 shares at DKK 300.03, for DKK 60,006,094 ^[1][2]. Those daily prices are above the DKK 281.63 average for the full program, which also includes purchases made earlier at lower prices ^[1][2].

Novo Nordisk now holds 46,074,876 of its own B shares, each with a face value of DKK 0.10, as treasury shares. That equals 1.0 percent of its share capital ^[1][2]. The company's total A and B shares, including treasury shares, come to 4,465,000,000 ^[1][2].

The notices do not say why Novo Nordisk is buying back stock, and they do not address medicine prices, supply, insurance coverage or clinical trials. Novo Nordisk is the company behind the semaglutide medicines Ozempic, Wegovy and Rybelsus; the buyback notices make no reference to those products ^[1][2].

Why it matters for patients

A share buyback is a financial transaction, not a change to a medicine. Novo Nordisk spending DKK 9.0 billion to buy its own stock does not alter which semaglutide products are on the market, how they are made, what they cost at the pharmacy, or whether an insurer covers them. The buyback notices contain no information on any of those subjects ^[1][2].

What the notices do describe is ownership math. Repurchased shares held as treasury shares do not vote or receive dividends while the company holds them, and a buyback reduces the number of shares counted in per-share measures such as earnings ^[2]. Novo Nordisk's treasury holdings equal 1.0 percent of its share capital ^[1][2].

For patients, any practical effect is indirect and long-term at most. Money spent on the company's own shares is cash that could otherwise go to growth or dividends, according to a filing summary, but the notices state no such plans ^[1][2]. Nothing reported changes a prescription, a dose, a prior authorization or a pharmacy's ability to fill an order, and no link between the buyback and the supply of any GLP-1 medicine is described ^[1][2].

What happens next

The buyback continues. The May 6 authorization runs through February 1, 2027, and the broader DKK 15 billion program covers the 12 months that began February 4, 2026 ^[1][2]. Novo Nordisk publishes the details of each transaction on its website ^[1][2].

What the company will do with the repurchased shares, and whether it will spend the full DKK 15 billion, has not been disclosed in the notices ^[1][2].